Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -2.05% and Operating profit at -6.81% over the last 5 years
2
The company has declared Negative results for the last 3 consecutive quarters
3
With ROE of 7.97%, it has a attractive valuation with a 1.24 Price to Book Value
4
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,762 Million (Mid Cap)
16.00
NA
2.39%
-0.57
7.97%
1.24
Revenue and Profits:
Net Sales:
979 Million
(Quarterly Results - Jun 2025)
Net Profit:
159 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
9.26%
0%
9.26%
6 Months
0%
0%
0.0%
1 Year
-8.93%
0%
-8.93%
2 Years
-2.75%
0%
-2.75%
3 Years
-2.9%
0%
-2.9%
4 Years
-41.44%
0%
-41.44%
5 Years
-0.17%
0%
-0.17%
Renhe Pharmacy Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.05%
EBIT Growth (5y)
-6.81%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.74
Tax Ratio
26.90%
Dividend Payout Ratio
43.09%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
25.78%
ROE (avg)
11.84%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
1.24
EV to EBIT
8.65
EV to EBITDA
6.84
EV to Capital Employed
1.56
EV to Sales
1.15
PEG Ratio
NA
Dividend Yield
2.39%
ROCE (Latest)
18.01%
ROE (Latest)
7.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
979.20
978.00
0.12%
Operating Profit (PBDIT) excl Other Income
219.00
197.80
10.72%
Interest
0.00
0.00
Exceptional Items
0.10
-0.00
Consolidate Net Profit
158.50
196.70
-19.42%
Operating Profit Margin (Excl OI)
193.40%
172.00%
2.14%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 0.12% vs 7.35% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -19.42% vs 280.46% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,028.20
4,983.00
-19.16%
Operating Profit (PBDIT) excl Other Income
796.10
1,090.20
-26.98%
Interest
3.30
3.70
-10.81%
Exceptional Items
-86.60
-185.90
53.42%
Consolidate Net Profit
566.60
629.40
-9.98%
Operating Profit Margin (Excl OI)
166.50%
189.30%
-2.28%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -19.16% vs -2.46% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -9.98% vs -11.54% in Dec 2023
About Renhe Pharmacy Co., Ltd. 
Renhe Pharmacy Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






